Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Low Dose Prednisolone in Severe Alcoholic Hepatitis
NCT06155760Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of prednisolone in alcoholic hepatitis (AH) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients achieving remission (mDF < 32) at 90 days. Status: unknown.
02
Drugs
prednisolone
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT06155760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06155760.